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Abstract
Advanced ovarian cancer remains a disease with a poor prognosis. Surgical therapy remains
the cornerstone of treatment with essential contribution from chemotherapy. The combina-
tion therapy continues to offer the best treatment strategy. Complete cytoreductive surgery
is still the most important prognostic marker. The role of primary debulking surgery in
advanced ovarian cancer remains under investigation through high quality rigorous clinical
trials. The current evidence regarding primary versus interval debulking surgery has drawn
much criticism regarding patient recruitment and quality of surgery, both of which are key
pillars in achieving complete cytoreduction. It is expected that greater centralisation and
development of ‘ovarian cancer surgery teams’ will further enhance clinical outcomes.
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1. Introduction
The surgical management of ovarian cancer has continued to evolve, particularly over the past
25 years.
The principles of cytoreductive surgery have been applied to not only the pelvic cavity but
also within the abdominal and thoracic cavity. The 5 year survival for this cohort of patients
has not significantly changed in the past 40 years. Presently clinical trials are examining the
role of effective cytoreductive surgery (CRS) and combination chemotherapy (including anti-
angiogenesis inhibitors, PARP inhibitors and immunotherapy) in optimising therapy. These
are likely to yield encouraging results in the next decade or two.
Imaging, role of lymphadenectomy and the management of recurrent ovarian cancer are
discussed elsewhere in this book. This chapter will describe the rationale and outcomes
associated with first line (either primary or interval) surgery for ovarian, tubal or primary
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peritoneal cancer. A technical description of the operative steps and intra-peritoneal chemo-
therapy are outside the scope of this chapter.
2. Peritoneal redistribution theory and carcinomatosis
Malignant spread of intraperitoneal tumours can occur via, local contiguous growth, non-
contiguous spread along mesenteric planes, haematogenous, lymphatic or transcoelomic
routes. Unlike the other routes, the transcoelomic pathway offers a rapid step change in
facilitating metastasis form multiple sites from within the abdomen. The parietal peritoneum
has both secretatory and absorptive functions. The omentum has an absorptive function. This
has been exploited in fashioning omental flaps to minimise incidence of inguinal lymphocyst
after lymphadenectomy or pelvic collection after exenteration.
The dynamics of peritoneal fluid is driven by secretion/adsorption by the peritoneum (in
particular right diaphragmatic peritoneum), recesses formed by the peritoneal reflections,
omental filtering, movement of diaphragm, negative pressure in the subdiaphragmatic region,
motility of viscera on mesentry and the resultant fluctuation in pressure differential within the
peritoneal cavity.
The ‘redistribution phenomenon’ was described by Sugarbaker in relation to pseudomyxoma
peritonei [1]. In this process free floating malignant cells and other debris utilise the movement
of peritoneal fluid (and the ascites produced) to become redistributed throughout the perito-
neal cavity. This includes the lesser sac. The absorption and filtering of the peritoneal fluid by
the greater and lesser omentum can result in debris and cells, including malignant cells,
becoming adherent to the omentum. This may in time result in ‘omental cake’ noted in
advanced ovarian cancer. Another major notable site of fluid absorption and disease conglom-
eration is the right hemidiaphragm. Gravitational distribution explains the deposits in the
Pouch of Douglas, paracolic gutters and subhepatic recesses. The mobile organs such as small
bowel are spared of deposits, early in the disease, whereas fixed retroperitoneal structures
such as ascending/descending colon and gastric pylorus may be affected. This would necessi-
tate resection of the organs.
3. Evolution of the concept of cytoreductive surgery
As early as in 1934, Meigs described that ‘removal of as much tumour as possible’ was
beneficial for survival [2]. In 1968 the British gynaecological surgeon Hudson described a
pioneering technique for the resection of ovarian cancer from the pelvis [3]. Although there
have been modifications, the principles have remained the same and his procedure is
recognised as the ‘radical oophorectomy’. This was an important step in CRS. In fact it was
the seminal work of Griffith’s published in 1975 which demonstrated that CRS associated with
smaller residual disease, can be linked to better survival in advanced ovarian cancer [4].
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Benefits of CRS include removal of poorly vascularised tissues (removing the pharmacological
sanctuary) and excising the chemoresistant clones. Therefore the resulting absent or minimal
disease will have more favourable cell kinetics with regard to chemosensitivity [5].
As the concept of CRS became more widely embraced, the application became more aggres-
sive. Disease on the diaphragm, large bowel, spleen or distal pancreas might have been
considered unresectable are now readily resected. Patient selection for these ultraradical pro-
cedures is important. This was a concern for the doubters as it may be associated with greater
risk of morbidity, delay in receiving chemotherapy as well as significant impact on the quality
of life (QOL) [6–8]. Indeed it was felt that perhaps only those with smaller volume and earlier
stage disease would benefit from aggressive CRS [5, 9]. However a structured approach to
quality improvement through enhanced skills, team structure and commitment to CRS has
been shown to improve extent of cytoreduction and hence overall median survival [10–12].
In an important meta-analysis, Bristow demonstrated that greater the volume reduction,
greater the survival outcome [13]. In fact they revealed that for every 10% increase in nil
residual disease, overall survival increased by 5.5% [13]. Similarly in a more recent meta-
analysis of largely newer data in the platinum-taxane era, Chang et al. demonstrated that with
each 10% increase in complete cytoreduction, the median overall survival improved by
2.3 months [14].
Three limitations to ultra-radical debulking surgery remain absence of grade A evidence
confirming that radical surgery is more efficacious than standard surgery, morbidity/mortality
associated with radical CRS and surgery in non-expert centres will only yield nil residual
disease in a relatively small proportion of patients [15]. The first two arguments are unlikely
to be resolved but one can certainly use big data to resolve treatment pathways for patients
with advanced disease.
4. Management of early stage ovarian cancer
In early stage ovarian cancer, the disease is confined to the ovaries or the upper genital tract.
Approximately 25% of ovarian cancer patients are diagnosed with stages 1 and 2. These
women generally have an excellent prognosis, provided a full staging procedure has been
performed. Proper staging allows identification of those who are truly early stage and those
who might have more advanced disease. This will allow optimal recommendation regarding
adjuvant chemotherapy for the apparent early stage patients [16]. The critical importance of
proper staging is underlined by the long term (10 year) follow up data offered by the ICON 1
study [17]. In this study the 10 year survival varied between 56 and 78% depending on the
completeness of staging [17].
Table 1 enumerates the steps in comprehensive surgical staging of suspected ovarian cancer.
Even in unilateral ovarian cancer, the risk of contralateral lymph node metastasis only, is 3.5%;
this is in addition to the 9.7% risk of metastasis on both sides and the 8.3% risk of ipsilateral
metastasis [18]. Indeed the risk of para-aortic lymph node metastasis only is 7.1% and the risk
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of pelvic and para-aortic lymph node metastasis is 4.3% [18]. Therefore comprehensive staging
should include bilateral pelvic and para-aortic lymphadenectomy. However, this may need to
be tempered by the overall clinical status of the individual patient. The single exception to this,
is early stage mucinous ovarian cancer in which the risk of lymph node metastasis is minor,
that omission of lymphadenectomy can be a safe option [19]. The extent of lymphadenectomy
appears to correlate with survival benefit, with better outcomes being associated with lymph
node counts of greater than 10 per site [18, 20].
5. Role of primary debulking surgery and neoadjuvant chemotherapy
Abundant retrospective data supported the notion of cytoreductive surgery [11, 14, 21]. The
standard treatment had been PDS followed by NACT. Where the initial PDS had not resulted
in ‘optimal debulking’ i.e. the residual disease was >1 cm in size, a second look laparotomy for
further debulking after 3 cycles of NACT had been the routine practice. Randomised studies
have examined this aspect and the most recent study by Rose et al. lead to the abandonment of
second look laparotomy [22]. Table 2 lists the procedures required for the ‘ultra-radical’
cytoreductive surgery which is in addition to the essential staging procedure.
The EORTC group led by Vergote conducted the first randomised trial comparing PDS followed
by adjuvant chemotherapy against IDS after 3 cycles of neoadjuvant chemotherapy [23]. The trial
Midline laparotomy
Obtain peritoneal fluid for cytology
Careful examination of all peritoneal surfaces
Total abdominal hysterectomy and bilateral salpingo-oophorectomy
Frozen section of ovarian mass  suspicious lesions
Infra-colic omentectomy
Appendicectomy (for mucinous tumours)
Peritoneal biopsy from diaphragmatic surface, four quadrants of the abdomen and pouch of Douglas
Pelvic and para-aortic lymphadenectomy
Table 1. Staging procedure for apparent early stage ovarian cancer.





Splenectomy  distal pancreatectomy
Segmental or lobular liver resection
Cholecystectomy
Diaphragmatic peritoneal stripping  segmental full-thickness resection of the diaphragm
Resection of suspicious or enlarged retroperitoneal lymph nodes
Resection of pleural disease  hycardiophrenic lymph nodes
Table 2. Potential procedures in ‘optimal’ cytoreductive surgery.
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recruited patients between 1998 and 2006. This was a time when both the surgical strategy with
respect to second-look laparotomy and ultra-radical surgery as well as chemotherapy regimens
was rapidly evolving.
In the EORTC 55971 study 670 patients were stratified and randomised to PDS or NACT
followed by IDS groups. The selection criteria included PS score and ‘severe disabling disease’
but resectability of the disease by a surgeon was not a condition. The study design did not
incorporate CT or laparoscopic scoring system in patient selection. At the time of surgery, in
the PDS arm 61% of patients had tumour size >10 cm and 24.2% of the same in the NACT arm;
the prevalence of these features at the time of randomisation was 39% in PDS and 42% in the
NACT arms. This suggests that a significant proportion of patients appear to have rather
aggressive disease. The median operation time was 165 min in PDS and 180 min in the NACT
arms. The proportion of patients in whom microscopic clearance was achieved was 19.4% in
PDS and 51.2% in the NACT arms. The splenectomy rates (5.8% in PDS, 4.0% NACT) and
bowel resection rates (15.5% in PDS, 8.7% in NACT) in this study are far lower than those
reported by other high volume centres at the same time [11]. The most frequent sites of
residual disease were pelvis, diaphragm and abdominal peritoneum; most experienced teams
would consider these sites technically resectable disease. In conjunction with other parameters
of cytoreduction mentioned above, one would find it difficult to be certain that the benefits of
upfront surgery could have been realised in these operatively unselected patients. The authors
acknowledge that a drawback of NACT is fibrosis which might impede tumour resection [23].
The CHORUS group recruited patients with clinical/radiological stage III and IV disease
between 2004 and 2010 [24]. Five-hundred and fifty-two women were randomised after strat-
ification by tumour size, stage, PS score and tumour markers as well as prespecified chemo-
therapy regime (single agent carboplatin, carbotaxol or carboplatin with another agent).
Patients received 6 cycles of chemotherapy in total with IDS performed after 3 cycles. The two
groups were comparable with similar proportions diagnosed as stage IIIC or IV (89% in PDS
and 87% in NACTarms). The median operation time was 120 minutes in both groups, which is
a remarkable short time for debulking surgery in advanced ovarian cancer. This consistent
with the rates of complete debulking achieved in arms, 17% in PDS and 39% in the NACT
arms. Indeed the suboptimal debulking (residual disease >1 cm) was very high at 59% in the
PDS and 27% in the NACT arms. These figures are out of kilt with data from high volume
international centres. The median overall survival was similar in both groups, but lower than
expected at 22.6 months for PDS and 24.2 months for NACT. Multivariate analysis did not
identify a subgroup favouring one treatment over another. The size of the residual tumour was
prognostic in both arms.
Overall the QOL parameters were comparable between the two groups, except at 6 months
post-treatment, the NACT group had higher scores. As expected the PDS group experienced
grade 3 and 4 adverse events more frequently than the NACT group with the exception of
haemorrhage. Death was more frequent in the PDS (6%) compared to the NACT (<1%) group.
The administration and toxicity of chemotherapy was comparable in both groups. The authors
acknowledged that the older median age, significant prevalence of poorly differentiated
tumour (77%) and high prevalence (19%) of poor performance (PS 2 or 3) status might have
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contributed to the less than expected overall survival. Indeed only 56% of patients received
combination chemotherapy in their first cycle if their PS was 2–3 but this increased to 72% if
their PS was 0–1. This differential has been recognised in the design of the currently recruiting
TRUST trial.
Indeed only 77% in the PDS and 79% in the NACT arms completed the allocated treatment
strategy.
Both EORTC 55971 and CHORUS trials have been heavily criticised [23, 24]. Indeed one would
have to question the rigour with which the peritoneal residual disease might have been
assessed in these two studies. For instance the incidence of peritoneal disease within the
omental bursa is in excess of 60% [25]. Adequate exploration of the omental bursa is an
advanced technique requiring assessment of coeliac nodes, caudate lobe, supragastric lesser
omentum and the recesses on the left lateral aspect. One cannot be certain if these steps had
been implemented in the earlier RCTs. Thus leading to inaccurate estimation of residual
disease. The potential issue of surgeon bias in estimating residual disease has been highlighted
in a radiological referencing study [26].
Indeed three further RCTs are examining the question of primary debulking surgery versus
neoadjuvant chemotherapy [27, 28]. In fact all three trials include physiological status of the
patient in their inclusion criteria. This feature was lacking in the CHORUS trial; EORTC 55971
excluded patients with PS 3 or ‘serious disabling disease’.
The Japanese studies (JCOG0602) and the Italian (SCORPION trial) studies have published the
peri-operative outcomes [27, 28]. As expected both of these studies demonstrate fewer peri-
operative complications, shorter length of stay and smaller blood loss after neoadjuvant che-
motherapy compared to primary debulking surgery.
The Japanese multicentre study recruited 301 between 2006 and 2011. In total, 8 cycles of
carboplatin and paclitaxol were administered. Those patients with a residual tumour of >1 cm
following PDS were offered IDS after 4 cycles of adjuvant chemotherapy. This is despite the
publication of GOG152 by Rose et al. in 2004 demonstrating no advantage to second look
laparotomy after a maximal effort at PDS [22]. Another peculiarity of this study is the interval
of more than 4 years between recruitment of the last patient and submission of the manuscript.
The ‘optimal debulking’ rate in this study, defined as residual tumour of <1 cm, was 82% in the
NACT and 37% in PDS group; when all treated patients are taken into account, including the
second-look laparotomy, then the optimal debulking rate changes to 71 and 63% in the NACT
and PDS arms respectively [28]. The grade 3–4 complications were less frequent after NACT
compared to PDS. Resection of ‘abdominal organs’ and ‘distant metastasis’ were more com-
mon after PDS. Curiously the duration of main surgery was longer in NACT (302 versus 240
min); this may be explained by the significantly higher rates of pelvic and para-aortic
lymphadenectomy in the NACT arm (pelvic LND 72.3% versus 27.2%; para-aortic LND
49.2% versus 11.6%) [28].
In the phase 3 Italian study, Fagotti and colleagues set out to investigate the best strategy for
managing patients with high tumour load [27]. Patients were recruited between 2011 and 2014.
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This is the first prospective randomised study seeking to verify a finding of an exploratory
analysis of EORTC 55971, which stated that for a subgroup of patients with large tumour
volumes, NACT lead to fewer morbidites and significantly better overall survival [29]. There-
fore the selection of patients for this SCORPION trial was guided by laparoscopic predictive
index (PI) [30, 31].Those patients with PI of >8 and < 12 were deemed eligible. In this study 55
were randomly assigned to each arm. None of the patients were subjected to a ‘second-look’
laparotomy. The cytoreductive rate to nil macroscopic disease was 45.5% in PDS arm and
57.7% in NACT arm. There was no significant difference in terms of the distribution of the
residual disease between the two arms—these were military disease on small bowel serosa,
hepatic hilum and nodal disease above the superior mesenteric artery. Upper abdominal pro-
cedures were carried out in 100% in the PDS and 42.3% in NACT arms. The surgical complex-
ity score was significantly higher in the PDS arm. As a result PDS was associated with longer
operating times and higher blood loss; this was accompanied by a mortality rate of 3.6% in the
PDS and none in the NACT arms. Three patients in the NACT arm were not submitted for
surgery due to disease progression. Many of the generic and specific parameters of QOL
measures were in favour of NACT; interestingly cognitive and social functioning showed
longitudinal improvement with the PDS group only. The oncological outcomes are awaited.
In due course, the findings of this study may complement those of the on-going TRUST trial.
The AGO initiated multicenter international trial, TRUST study (NCT02828618), aims to
address many of the short comings identified in the EORTC 55971 and the CHORUS studies.
These are addressed by applying selection criteria with regards to the patients, disease and
surgical team characteristics. Unlike any of the earlier RCTs in evaluating the timing of surgery
in advanced epithelial ovarian cancer, involvement in the TRUST trial will entail an audit of
the participating centres prior to study engagement. This ensures that the surgeon(s), surgical
team and the relevant infrastructure are in place to deliver the most optimal cytoreductive
surgery. The study is expected to complete recruitment in 2023. The outcomes of interest
include surgical complications at 28 days, clinical outcomes at 1 year, QOL as well as oncolog-
ical measures at 5 years.
6. Predictors of optimal cytoreduction
The two most important prognostic characteristics in ovarian cancer are comprehensive stag-
ing and optimal cytoreductive surgery [21]. Disease morphology (as predicted by cross sec-
tional imaging and/or laparoscopic assessment), physiological fitness of the patient and the
skill set of the surgeon or surgical team are the three key domain determining the resectability.
Since we have long abandoned the concept of second look laparotomy, it is important that
where risk of residual exists, we must seek alternatives to primary debulking surgery, other-
wise the patient may be dealt with a treatment strategy which is overall suboptimal. Therefore
can biochemical, molecular imaging or endoscopic assessment help predict optimal surgery?
This subject is a vast area and it will be briefly reviewed here in the context of cytoreductive
surgery for advanced ovarian cancer.
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The reader should exercise caution in interpreting results from studies for two key reasons;
each study will use a different protocol for the index test of interest and secondly the assess-
ment of residual disease is not without bias [32].
Several studies have demonstrated that preoperatively raised level of CA125 and HE4 can
predict suboptimal debulking [33–35]. Indeed higher platelet count, lower lymphocyte count
or higher ratio of platelet to lymphocyte count can predict suboptimal debulking in advanced
ovarian cancer [36, 37].
Functional imaging such as diffusion weighted MRI and PET-CT are rapidly evolving. The key
aspect for imaging should be able to identify the rate limiting steps in relation to cytoreductive
surgery. Diseases on small bowel mesentry and bowel serosa are consistently the rate limiting
steps in delivering microscopic clearance of the disease. At present there is significant interest
in diffusion weighted MRI and a prospective imaging study is underway to delineate the role
of multiplanar MRI with CT as compared with standard CT alone in guiding decision making
process (ISRCTN51246892). In a recent paper, the dwMRI appears to perform very well in
predicting disease map [38]. The role of CT on its own in predicting resectability provides does
not provide a consistent acceptable answer particularly as the current standard of ‘optimal’
debulking is nil visible disease [39–41].
Laparoscopic assessment can be useful adjunct in patient selection. One must acknowledge
that a laparoscopic assessment can only provide information regarding the intraperitoneal
disease. Fagotti and colleagues have accomplished a body of work regarding the role of
laparoscopy in advanced ovarian cancer. Studies have consistently shown that small bowel
and its mesentry are common site for the residual disease [27, 31, 42]. Petrillo et al. de on
laparoscopic assessment, where unresectability is indicated by a predictive score of greater
than 8 [31].
It is likely that a combination of metabolic analysis and morphologic characteristics will
enhance non-invasive prediction of resectability in the medium future.
7. Optimising cytoreductive surgery
In the United Kingdom, the chief medical officer, Professor Dame Sally Davies recommended
that ‘the Royal College of Obstetricians and Gynaecologists should make sure that sub-
specialist training in gynaecological oncology equips doctors to perform optimal surgery for
gynaecological cancers and reduce mortality from ovarian cancer’ [43].
Both modifiable (technical skills, organisation of care) and constitutional (e.g. age, biology,
functional status) factors need to be addressed if we are to make incremental improvements in
the outcomes for our patients.
One approach to this could frame any death from ovarian cancer as an ‘error’. With such an
approach one can adopt a sophisticated approach to addressing the modifiable factors [44, 45].
Vincent and colleagues articulated seven levels at which an error should be tackled. These are
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institutional (and national climate), organisation & management, work environment, team,
individual staff member, task and patient [45]. How this model could be used for maximising
optimal cytoreductive surgery is briefly illustrated here.
The statement by the CMO above creates a national sense of the overall aim. In addition, the
European Society of Gynaecological Oncology (ESGO) published a benchmark regarding
ovarian cancer surgery, which adds to this impetus, about the desirable end goal [46]. This
expert consensus report recommends 10 indicators relating to structural, process and outcome
metrics ranging from individual performance to team decision making process within a
multidisciplinary setting. Such a suite of benchmarks can set the direction of travel.
Around the globe and even within the ‘developed’ nations the practice of patient selection,
planning and delivery of upfront surgery varies a great deal. Therefore in terms of organisa-
tion and management, centralization of care delivery will help optimise outcomes [26, 47].
With regard to team and individual factors, training should target both and the end goal
should be clear to both entities, that is, microscopic clearance of the disease. The delivery of
surgery could be by a sufficiently trained gynaecological oncologist with the appropriate
contribution from allied surgical oncologists. ESGO have organised or sponsored numerous
workshops targeting technical skills and the philosophy to support primary debulking sur-
gery. Such a concerted effort will help to redress one of the concerns about current training.
The application of the current ‘gold standard’ evidence from two randomised controlled trials,
(though heavily criticised) will adversely impact the training of the next generation of sur-
geons. Further, the timing of TRUST trial outcome and retirement of those trained prior to the
wide acceptance of PDS, will change the landscape of practitioners.
Indeed individual and team training can be augmented by not only skills training in work-
shops, but through buddy operating during the transition phase. Such an endeavour could be
supported by virtual platforms to maintain skills (e.g. video based feedback on specific sub-
tasks in cytoreductive surgery) [48, 49]. This will augment task performance.
Patient selection is discussed elsewhere in this book and will not be discussed here. The factors
will include demographic, biological (including molecular characteristics of the disease) and
radiomics to mention a few [50].
Another important measure in improving the outcomes as part of CRS is to enhance chemo-
therapy with the use of Hyperthermic Intraperitoneal Chemotherapy (HIPEC). In a recent
study, addition of HIPEC to CRS appears to prolong the overall survival by almost 12 months
in patients undergoing interval debulking surgery [51]. This offers an exciting complement to
maximal effort CRS. These findings will require independent verification prior to widespread
adaptation. This topic will not be discussed further in this chapter.
8. Conclusions
At present the grade A evidence reveals no significant difference in the 5 year survival
amongst patients receiving either primary or interval debulking surgery for ovarian cancer. It
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must be borne in mind that the evidence base is not without significant criticism. It is likely
that on-going surgical and medical trials in ovarian cancer will alter our management of this
heterogeneous entity. Clinicians will appreciate that given the morbidity of cytoreductive
surgery, development of this service requires appropriate governance structure.
How to optimise surgery: will involve better characterisation of the disease through molecular
stratification, better selection of patients in terms of physiological fitness (so reduce complica-
tions), continued training of surgeons & teams, centralization of service for those who would
be best suited for maximal effort surgery.
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